Determination and pharmacokinetics of MN9202 in Beagle dogs

AIM: To set up a sensitive and rapid high performance liquid chromatography (HPLC) method to determine MN9202 and to study its pharmacokinetics in Beagle dogs. METHODS: The mobile phase and extraction methods were optimized by the orthogonal experimental design. MN9202 was intravenously administered to the Beagle dogs at the dose of 0.335 mg/kg and MN9202 in plasma was detected by HPLC. The pharmacokinetic parameters were calculated by 3P97 software. RESULTS: Under the selected HPLC conditions, the MN9202 was clearly separated from interference and the retention time of MN9202 was less than 14 min. When MN9202 was intravenously administered, the plasma concentration-time curve was fit to two-compartment model. T 1/2 β was (200±32) min. and AUC was (32 147± 9544)μg·min/L. CONCLUSION: The analytical method we set up is simple, sensitive and accurate, and it can be applied to determine the MN9202 in the plasma of Beagle dogs. The speed of elimination of MN9202 is high in Beagle dogs.